What is HC Wainwright’s Forecast for KTTA FY2025 Earnings?

by · The Cerbat Gem

Pasithea Therapeutics Corp. (NASDAQ:KTTA – Free Report) – Equities researchers at HC Wainwright issued their FY2025 EPS estimates for shares of Pasithea Therapeutics in a research report issued on Monday, December 8th. HC Wainwright analyst S. Nik anticipates that the company will post earnings per share of ($1.50) for the year. HC Wainwright currently has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ Q4 2025 earnings at ($0.18) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.82) EPS and FY2028 earnings at ($0.87) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Monday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.00.

Read Our Latest Report on KTTA

Pasithea Therapeutics Trading Up 3.5%

Shares of KTTA opened at $1.17 on Wednesday. The company has a market cap of $8.70 million, a P/E ratio of -0.23 and a beta of 0.21. Pasithea Therapeutics has a twelve month low of $0.28 and a twelve month high of $3.85. The company’s fifty day simple moving average is $0.80 and its 200-day simple moving average is $0.77.

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.41) EPS for the quarter.

Institutional Investors Weigh In On Pasithea Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KTTA. AdvisorShares Investments LLC grew its position in shares of Pasithea Therapeutics by 261.5% during the 2nd quarter. AdvisorShares Investments LLC now owns 193,547 shares of the company’s stock worth $140,000 after buying an additional 140,000 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Pasithea Therapeutics in the third quarter valued at about $26,000. Finally, Citadel Advisors LLC lifted its stake in Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after acquiring an additional 20,483 shares during the period. 23.92% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Lawrence Steinman acquired 133,333 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were bought at an average price of $0.75 per share, with a total value of $99,999.75. Following the completion of the purchase, the director directly owned 199,691 shares in the company, valued at $149,768.25. This trade represents a 200.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased a total of 199,999 shares of company stock valued at $149,999 in the last ninety days. 2.70% of the stock is currently owned by insiders.

Pasithea Therapeutics Company Profile

(Get Free Report)

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.

Further Reading